Should I Buy ALZN? ALZN 2026 Analysis

Should You Buy Alzamend Neuro Inc (ALZN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.020

1 Day change

-6.48%

52 Week Range

10.710

Analysis Updated At

2026/01/28

Not a good buy right now for a beginner long-term investor with $50k–$100k and low patience. ALZN shows weakening momentum (bearish MACD), is trading below/near key support in pre-market (2.12 vs S1 2.164 and close to S2 2.068), has no recent catalysts, and the latest quarter (2026/Q2) shows no revenue and worsening losses. With no Intellectia buy signals active, the risk/reward is unfavorable for your profile—avoid/exit rather than buy today.

Technical Analysis

Pre-market price is 2.12, which is below the pivot (2.318) and under the first support S1 (2.164), putting the stock in a technically weak zone and vulnerable to testing S2 (2.068). MACD histogram (-0.0109) is below zero and negatively expanding, signaling bearish momentum is strengthening. RSI(6) at ~39.4 is neutral-to-weak (not oversold enough to imply a high-confidence bounce). Moving averages are converging, suggesting indecision, but with price below pivot/support and bearish MACD, the bias remains downward unless it reclaims 2.318 and holds above it. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Positive Catalysts

No news in the recent week; no clear event-driven catalyst is identified from the provided data. A potential short-term technical bounce could occur only if price holds above ~2.07 (S2) and recovers toward 2.32 (pivot), but this is not supported by a current buy signal.

Neutral/Negative Catalysts

Bearish momentum is increasing (MACD negatively expanding) while price is already below key support levels. Lack of recent news/catalysts reduces the chance of a rapid sentiment-driven recovery. Trading trends show hedge funds and insiders are neutral (no supportive accumulation signal).

Financial Performance

Latest quarter: 2026/Q2. Revenue remained at 0 (no operating revenue). Net income worsened to -1,000,758 (down 29.29% YoY) and EPS dropped to -0.30 (down 91.69% YoY). This indicates deteriorating profitability with no demonstrated top-line growth, which is unfavorable for a long-term beginner-focused buy case.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided. Based on available information, there is no observable Wall Street endorsement trend to support a long-term buy, and the fundamentals/technical setup skew to the downside.

1 Analyst Rating

Wall Street analysts forecast ALZN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALZN is 28 USD with a low forecast of 28 USD and a high forecast of 28 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.160

Low

Averages

High

Current: 2.160

Low

Averages

High

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$32 → $20

AI Analysis

2025-03-17

Reason